Table 4.

Incidence of premonitory symptoms that were followed by headache prior to galcanezumab treatment

	Incidence %
Premonitory symptoms	All patients	Responders	Non responders	Fisher exact
Neck stiffness	54.3	59.3	47.4	0.550
Cognitive impairment	54.3	63.0	42.1	0.231
Photophobia	39.1	48.1	26.3	0.21
Irritability	39.1	48.1	26.3	0.219
Fatigue	37.0	44.4	26.3	0.235
Stress/nervous	32.6	33.3	31.6	1.000
Vertigo/dizziness	30.4	37.0	21.1	0.335
Nausea	28.3	29.6	26.3	1.000
Phonophobia	28.3	40.7	10.5	0.044
Osmophobia	17.4	22.2	10.5	0.439
Ringing in the ear	15.2	18.5	10.5	0.682
Yawning	13.0	22.2	0.0	0.034